Latigo Biotherapeutics (LTGO) News
NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.00-0.24 (-1.81%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LTGO news summary
We found 3 recent headlines mentioning Latigo Biotherapeutics (LTGO): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Seeking Alpha. For price context, LTGO is down 1.81% at $13.00. The most recent story, "Latigo Biotherapeutics, Inc. GAAP EPS of -$0.55 beats by $0.12", was published by Seeking Alpha on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Latigo Biotherapeutics headlines
- Latigo Biotherapeutics, Inc. GAAP EPS of -$0.55 beats by $0.12Seeking Alpha
- Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPhase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027GlobeNewswire
- Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of GrowthTodd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and…GlobeNewswire